Pari gbolohun ti o tẹle: Lati yọ igbẹkẹle kuro ni Ilu China lẹhin ti
2017 China India border standoff to foster an Atmanirbhar Bharat, in July 2021 India's Council of Scientific and Industrial Research (CSIR) initiated a Make in India program in collaboration with the coal and petroleum industries of India to end-to-end manufacture 56 priorityised active pharmaceutical ingredient (API) for the essential medicines. Ní July 2021, ìgbìmọ̀ ìwádìí sáyẹ́ǹsì àti ọ̀rọ̀-ìṣègùn ní Íńdíà (CSIR) bẹ̀rẹ̀ ètò 'Ṣe ní Íńdíà' (Make in India) ní ìfọ̀wọ́sowọ́pọ̀ pẹ̀lú àwọn iléeṣẹ́ epo rọ̀bì àti epo rọ̀bì ní Íńdíà láti ṣe àwọn oògùn tó ṣe kókó fún àwọn oògùn tó ṣe kókó. Ni ọdun 2016-17, China ni olupese ti o tobi julọ ti API si India pẹlu ipin 66% nipasẹ iwọn didun ti awọn ipese ohun elo aise API si India ti o tọ US $ 2.4 bilionu tabi INR 18,000 crore, atẹle nipasẹ US $ 1.6 bilionu ti API ti a gbe wọle lati Germany, AMẸRIKA, Italy ati Singapore jẹ awọn olupese pataki miiran si India.